VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
HNGE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HNGEHinge Health, Inc.
$114.41$8.9B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksHNGECash Flow

Hinge Health, Inc. (HNGE) Cash Flow Statement

3Y historyFree accessUpdated daily

Free cash flow reached $112.7M in 2026Q3 at a 47.9% margin with capital expenditures below 1% of revenue, while $105.0M went to buybacks in 2026Q1 and $97.4M to net acquisitions in 2026Q3, so sustained conversion depends on working capital swings such as the $22.0M and $14.4M inflows in recent quarters.

Income StatementBalance SheetCash FlowRatios

HNGE Cash Flow Statement

Annual statement

HNGE Cash Flow Statement

Hinge Health, Inc. (HNGE) cash flow statement — 3-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23
Cash from Operations322.99M171.44M49M-63.91M
Operating CF Margin %-29.16%12.55%-21.83%
Operating CF Growth %1281.95%249.87%176.67%-
Net Income168.31M-528.26M-11.93M-108.14M
Depreciation & Amortization5.68M5.13M5.95M5.63M
Stock-Based Compensation67.5M643.01M739K1.65M
Deferred Taxes-3.39M53K-585K-473K
Other Non-Cash Items71.95M53.52M41.33M28.02M
Working Capital Changes12.95M-2.01M13.5M9.41M
Change in Receivables-58.42M-26.63M-1.34M-23.13M
Change in Inventory-5.08M-4.76M608K10.56M
Change in Payables17.01M29.41M-10.97M0
Cash from Investing-25.17M-113.76M18.31M1.5M
Capital Expenditures-2.56M-708K-1.04M-1.98M
CapEx % of Revenue0.32%0.12%0.27%0.68%
Acquisitions-97.35M-4M00
Investments----
Other Investing-14.17M-5.36M-2.73M-2.64M
Cash from Financing-345.13M-150.47M-2.2M-3M
Debt Issued (Net)0000
Equity Issued (Net)-205.51M200.18M610K0
Dividends Paid0000
Share Repurchases-222.41M-65.03M00
Other Financing-139.62M-350.64M-2.81M-3M
Net Change in Cash-47.31M-92.79M65.11M-65.41M
Free Cash Flow318.7M170.73M45.23M-68.52M
FCF Margin %39.8%29.04%11.59%-23.41%
FCF Growth %125.78%277.49%166%-
FCF per Share3.682.090.58-0.88
FCF Conversion (FCF/Net Income)1.89x-0.32x-4.11x0.59x
Interest Paid0000
Taxes Paid0000

Key Metrics

Growth RegimeExpanding
ProfitabilityModerate
Balance SheetAdequate
Cash FlowImproving
Top Statement Risk

Conversion dependent on working capital swings

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Operating Cash Flow Outpaces Reported Earnings

Based on reported figures, HNGE generated $114.6M of operating cash flow against $57.4M of net income in 2026Q3, an OCF-to-net-income ratio of 2.00 that suggests earnings are being backed by real cash generation rather than accruals.

The ratio held near 2.0 in both 2026Q1 and 2026Q2 aside from a weaker 1.23 in Q1, which points to working capital timing rather than structural weakness. Large non-cash add-backs such as stock-based compensation of $19.5M in the latest quarter contribute to the gap, so the conversion strength partly reflects non-cash expense treatment that investors should keep in view. The sustainability of this conversion depends on whether working capital inflows of $14.4M prove repeatable.

Free Cash Flow Margin Reaches Near Half of Revenue

According to recent SEC filings, HNGE's free cash flow margin reached 47.9% in 2026Q3 after 46.8% in 2026Q2, up sharply from 15.6% in 2024Q2, indicating a rapid shift toward self-funding operations.

Capital expenditure is negligible at 0.8% of revenue, so nearly all operating cash converts into free cash flow, which makes the margin more sensitive to working capital and SBC treatment than to investment needs. The move from a near-breakeven Q1 2025 FCF of $4.2M to $112.7M in the latest quarter signals meaningful operating leverage. Investors should monitor whether margins hold once working capital tailwinds fade.

Asset-Light Model Limits Reinvestment Needs

Based on reported figures, HNGE's capital expenditures remained below 1% of revenue across the last several quarters, with the latest quarter at $1.9M, consistent with a platform business that delivers care largely through software and contracted clinicians.

The minimal capex profile implies that the company's cash needs are driven by operating expenses such as clinical labor and customer acquisition rather than fixed asset investment. Depreciation and amortization of $2.2M in 2026Q3 sits well above capex, which may reflect amortization of previously capitalized development or hardware, warranting further investigation into the accounting for those assets. Low capital intensity supports high cash conversion but leaves the model exposed to any future hardware refresh cycle.

Cash Directed Toward Buybacks and Acquisitions

As reported in financial statements, HNGE deployed $105.0M into share repurchases in 2026Q1 and $97.4M into net acquisitions in 2026Q3, with no dividends paid across the period shown.

Capital deployment has shifted from balance sheet accumulation toward active buybacks and acquisitions once free cash flow scaled, which suggests management views internally generated cash as sufficient to fund both. The lumpy pattern of repurchases, with $65.0M in Q4 2025 and $25.9M in Q3 2026 among other quarters, indicates opportunistic rather than programmatic execution. Returns on these acquisitions cannot be assessed from the supplied data and warrant further review.

Cumulative Cash Reality Lags Net Income Volatility

Based on reported figures, HNGE's 2025Q2 net loss of $575.7M was driven by a $591.0M non-cash charge, while operating cash flow stayed positive at $20.2M, illustrating how reported earnings and cash generation have diverged sharply in individual quarters.

Over the 10-quarter window, the pattern of large GAAP swings alongside steadily rising operating cash flow suggests the reported net income series is distorted by non-cash items rather than reflecting underlying cash economics. The $121.3M net income in 2025Q1, far above its operating result, further indicates non-operating gains that do not translate to cash. An analyst should treat the cumulative cash series as the more reliable indicator of earnings power.

Stock-Based Compensation Flatters Cash Metrics

According to recent SEC filings, HNGE's operating cash flow adds back $19.5M of stock-based compensation in 2026Q3, meaning a portion of the cash strength reflects equity dilution rather than cash-costed labor and sales expense.

Because SBC is excluded from operating cash flow, free cash flow margins of 47.9% may overstate the economic cash generated for shareholders once dilution is considered. The 2025Q2 SBC figure of $591.0M also suggests a very large equity-related charge that bears watching for future dilution impact. Investors should evaluate free cash flow after SBC to gauge true owner economics, which may materially reduce the headline margin.

HNGE — Frequently Asked Questions

Quick answers to the most common questions about buying HNGE stock.

How much cash does Hinge Health, Inc. (HNGE) generate from operations?

Hinge Health, Inc. (HNGE) generated $171.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Hinge Health, Inc.'s free cash flow?

Hinge Health, Inc. (HNGE) generated $170.7M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Hinge Health, Inc.'s capital expenditure (CapEx)?

Hinge Health, Inc. (HNGE) spent $0.7M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Hinge Health, Inc. distribute cash to shareholders?

In 2025, Hinge Health, Inc. (HNGE) spent $65.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.